ArticleMicrobial cell factories2026
Biosensor-driven evolution and metabolic engineering of an Escherichia coli cell factory for L-tryptophan production.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
L-Tryptophan is an important aromatic amino acid with wide applications across the food, pharmaceutical, and feed industries. However, its efficient microbial production remains challenging due to complex metabolic networks and multi-level feedback regulation. In this study, we constructed a highly efficient Escherichia coli cell factory for L-tryptophan biosynthesis by combining systematic metabolic engineering with high-throughput screening. Initially, a tnaC-based biosensor was developed and coupled with atmospheric and room temperature plasma (ARTP) mutagenesis to isolate high-performance chassis strains. Central carbon metabolism was subsequently reprogrammed to minimize carbon loss and channel metabolic fluxes toward essential precursors, phosphoenolpyruvate (PEP) and erythrose-4-phosphate (E4P). To further alleviate pathway bottlenecks, promoter engineering was utilized to balance the intracellular supplies of L-glutamine, L-serine, and phosphoribosyl pyrophosphate (PRPP). This targeted intervention yielded a 21.61% increase in L-tryptophan accumulation. Product transport systems were then engineered to enhance extracellular secretion and mitigate intracellular toxicity. Following the optimization of inoculum size and feeding strategies in a 5 L bioreactor, the final engineered strain (W-24) produced 50.83 g/L of L-tryptophan within 40 h, achieving a yield of 0.185 g/g glucose. This multi-modular engineering framework establishes a robust platform for L-tryptophan biosynthesis and provides a scalable strategy for the industrial production of other valuable aromatic compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.